BofA analyst Adam Ron downgraded Alignment Healthcare to Neutral from Buy with a price target of $7.25, down from $7.50. While the firm continues to view Alignment as a “high quality company” positioned for above average growth in the Medicare Advantage, the fastest growth subsector in managed care, it notes the company has talked down expectation for near-term profitability and sees a more balanced risk/reward at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALHC:
- Alignment Healthcare Reports Third Quarter 2023 Results; Exceeds Guidance Across All Key Financial Metrics
- Alignment Healthcare Medicare Advantage Plan Named to U.S. News & World Report 2024 Best Insurance Companies for Medicare Advantage in North Carolina for Second Consecutive Year
- Alignment, Walgreens to introduce co-branded Medicare advantage plans
- Alignment Healthcare and Walgreens to Introduce Co-Branded Medicare Advantage Plans in Select Markets in 2024
- Alignment Healthcare California, North Carolina Medicare receive high scores